• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Basic Materials·CHEMFAB.NS
Share

Chemfab Alkalis Limited Stocks

₹ 366.1Last Updated 24.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 54.52M

₹ 366.1
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1985 and headquartered in Chennai, India, Chemfab Alkalis Limited is an international manufacturer and vendor of inorganic chemical products. The company's business activities are structured around two main segments: Chemicals and Related Products/Services, and PVC-O Pipes. Its comprehensive product range includes various chemicals like caustic soda (available in lye and flake forms), liquid chlorine, hydrogen gas, hydrochloric acid, and sodium hypochlorite/bleach liquor, in addition to industrial-grade and edible salt varieties. Formerly operating as Teamec Chlorates Limited, the company officially adopted its current name, Chemfab Alkalis Limited, in July 2017.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 01:43

The S&P 500 and the Dow closed higher amid falling oil prices

27.07.2026 23:55

"Just Like a Nike Sneaker Drop": Ford Has Figured Out How to Boost Profits Through Customization

27.07.2026 23:27

Dior's owner reported an increase in sales of clothing and handbags for the first time in two years

27.07.2026 22:53

Nvidia formed an AI safety alliance following an accidental hack carried out by OpenAI

27.07.2026 22:30

Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026